Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
QuidelOrthoQDEL -24.91%45 Debt-to-EBITDA is 33.82 as of Jun. 2026, which is 4128% above its 10-year median of 0.80. GuruFocus rates QDEL with a GF Score™ of 45/100 and a GF Value™ of $34.29 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 471 Medical Devices & Instruments companies, QuidelOrtho ranks worse than 212314.01% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for QuidelOrtho's Debt-to-EBITDA or its related term are showing as below:
QDEL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.02 Med: 0.8 Max: 9.86
Current: -6.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of QuidelOrtho was 9.86. The lowest was -6.02. And the median was 0.80.
QDEL's Debt-to-EBITDA is ranked worse than 100% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs QDEL: -6.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
QuidelOrtho Debt-to-EBITDA Related Terms
QuidelOrtho Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for QuidelOrtho's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QDEL vs LMRI, AVNS, TNDM: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, QuidelOrtho's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QuidelOrtho Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where QuidelOrtho's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
QuidelOrtho (QDEL) has a Debt-to-EBITDA of 33.82 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on QuidelOrtho. This is 4128% above median its historical median of 0.80. According to the industry distribution chart, QuidelOrtho ranks #999999 out of 471 companies in the Medical Devices & Instruments industry.
Is QuidelOrtho's Debt-to-EBITDA too high?
QuidelOrtho's current Debt-to-EBITDA of 33.82 is 4128% above median its 10-year median of 0.80. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. QuidelOrtho's value of 33.82 is 1962.2% above this industry median. Based on the distribution chart, QuidelOrtho ranks #999999 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, QuidelOrtho has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does QuidelOrtho's Debt-to-EBITDA compare to LMRI and AVNS?
According to the Medical Devices & Instruments industry distribution chart, QuidelOrtho ranks #999999 out of 471 companies for Debt-to-EBITDA. This places QuidelOrtho in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. QuidelOrtho's value of 33.82 is 1962.2% above this benchmark. While the company's 10-year median is 0.80 vs. the industry median of 1.64, QuidelOrtho has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. QuidelOrtho's current Debt-to-EBITDA of 33.82 is 1962.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on QuidelOrtho. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QuidelOrtho's current Debt-to-EBITDA is 33.82, which is 4128% above median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QuidelOrtho stock overvalued right now?
Based on GuruFocus' analysis, QuidelOrtho (QDEL) is currently considered Possible Value Trap. The stock's GF Value™ is $34.29, compared to a current price of $12.29 — trading 64.2% below its estimated fair value. The current Debt-to-EBITDA is 33.82, which is 4128% above median its 10-year median of 0.80 and 1962.2% above the Medical Devices & Instruments industry median of 1.64. QuidelOrtho's overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For QuidelOrtho (QDEL), the current Debt-to-EBITDA is 33.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is QuidelOrtho (QDEL) Overvalued in 2026?
Based on GuruFocus' analysis, QuidelOrtho stock appears to be undervalued.
The current stock price of $12.29 is trading 64.2% below its estimated GF Value™ of $34.29.
GuruFocus considers QuidelOrtho to be Possible Value Trap.
Key valuation signals for QDEL:
Debt-to-EBITDA: 33.82 (4128% above median its 10-year median of 0.80)
GF Value™: $34.29 vs. price of $12.29 (64.2% below fair value)
Industry Position: 1962.2% above the Medical Devices & Instruments median (#999999 of 471)
No single metric tells the full story. See the QDEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
45GF Score
Get the complete analysis for QDEL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QDEL has been successfully added to your 
